•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
BioNTech SE (Nasdaq: BNTX) will announce its financial results for the first quarter of 2026 on Tuesday, May 5, 2026. The company will also host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts, and the general public to discuss the results and provide a corporate update.
To access the live conference call via telephone, participants must register in advance. After registering, dial-in numbers and a PIN will be provided, and the company recommends registering at least one day before the call.
The slide presentation and audio of the webcast will be available via a link provided through the company’s communications. Participants can also access the slides and webcast through the “Events & Presentations” page in BioNTech’s Investor Relations section.
A replay of the webcast will be made available shortly after the call and will be archived on the company’s website for 30 days following the call.
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company focused on novel investigative therapies for cancer and other serious diseases. The company uses computational discovery and therapeutic modalities to develop biopharmaceuticals, with a diversified oncology portfolio of product candidates designed to address the full continuum of cancer.
BioNTech’s oncology pipeline includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cell therapies. The company also develops mRNA vaccine candidates for a range of infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities.
BioNTech has relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Genentech (a member of the Roche Group), Genmab, MediLink, OncoC4, Pfizer, and Regeneron.
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
